Free Trial
NASDAQ:CRIS

Curis (CRIS) Stock Price, News & Analysis

Curis logo
$1.46 -0.64 (-30.48%)
Closing price 04:00 PM Eastern
Extended Trading
$1.49 +0.03 (+1.78%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Curis Stock (NASDAQ:CRIS)

Key Stats

Today's Range
$1.40
$2.13
50-Day Range
$1.46
$3.52
52-Week Range
$1.42
$17.49
Volume
290,334 shs
Average Volume
59,981 shs
Market Capitalization
$12.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Remove Ads

Curis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

CRIS MarketRank™: 

Curis scored higher than 50% of companies evaluated by MarketBeat, and ranked 567th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Curis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Curis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Curis' stock forecast and price target.
  • Earnings Growth

    Earnings for Curis are expected to grow in the coming year, from ($7.12) to ($3.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Curis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Curis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Curis has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Curis' valuation and earnings.
  • Percentage of Shares Shorted

    1.93% of the float of Curis has been sold short.
  • Short Interest Ratio / Days to Cover

    Curis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Curis has recently increased by 1.19%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Curis does not currently pay a dividend.

  • Dividend Growth

    Curis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.93% of the float of Curis has been sold short.
  • Short Interest Ratio / Days to Cover

    Curis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Curis has recently increased by 1.19%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Curis has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Curis this week, compared to 1 article on an average week.
  • MarketBeat Follows

    4 people have added Curis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Curis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.70% of the stock of Curis is held by insiders.

  • Percentage Held by Institutions

    Only 29.97% of the stock of Curis is held by institutions.

  • Read more about Curis' insider trading history.
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

CRIS Stock News Headlines

Curis Stock Price, Quotes and Forecasts
Curis price target lowered to $16 from $20 at H.C. Wainwright
Trump… a socialist?
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Curis, Inc.: Curis Provides Fourth Quarter 2024 Business Update
See More Headlines

CRIS Stock Analysis - Frequently Asked Questions

Curis' stock was trading at $3.06 on January 1st, 2025. Since then, CRIS stock has decreased by 52.3% and is now trading at $1.46.
View the best growth stocks for 2025 here
.

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings results on Monday, March, 31st. The biotechnology company reported ($1.25) EPS for the quarter, beating analysts' consensus estimates of ($1.36) by $0.11. The biotechnology company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.04 million. Curis had a negative net margin of 443.35% and a negative trailing twelve-month return on equity of 923.37%.

Curis shares reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Micron Technology (MU), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), NIO (NIO), Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/01/2024
Today
4/01/2025
Next Earnings (Estimated)
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CRIS
Employees
60
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$26.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+1,100.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-47,410,000.00
Net Margins
-443.35%
Pretax Margin
-443.35%

Debt

Sales & Book Value

Annual Sales
$10.26 million
Price / Cash Flow
N/A
Book Value
$3.34 per share
Price / Book
0.52

Miscellaneous

Free Float
7,984,000
Market Cap
$14.82 million
Optionable
No Data
Beta
3.49

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CRIS) was last updated on 4/1/2025 by MarketBeat.com Staff
From Our Partners